Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma

被引：4

作者：

Ambady, Prakash ^{[1
]}

Fu, Rongwei ^{[2
]}

Szidonya, Laszlo ^{[1
]}

Peereboom, David M. ^{[3
]}

Doolittle, Nancy D. ^{[1
]}

Neuwelt, Edward A. ^{[1
,4
,5
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA

[2] Oregon Hlth & Sci Univ, Sch Publ Hlth, Dept Clin Epidemiol & Med Informat, Portland, OR 97201 USA

[3] Cleveland Clin, Burkhardt Brain Tumor Ctr, Cleveland, OH 44106 USA

[4] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA

[5] Portland VA Med Ctr, Portland, OR 97239 USA

来源：

JOURNAL OF NEURO-ONCOLOGY | 2020年 / 147卷 / 01期

关键词：

Primary CNS lymphoma; Maintenance therapy; Rituximab; High-dose methotrexate; PRIMARY CNS LYMPHOMA; BLOOD-BRAIN-BARRIER; CHEMOTHERAPY; METHOTREXATE; DISRUPTION; SURVIVAL; THERAPY;

D O I：

10.1007/s11060-020-03411-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose The role of maintenance immunotherapy with anti-CD20 monoclonal antibody rituximab in primary central nervous system lymphoma (PCNSL) is unclear. We retrospectively reviewed the medical records of all immunocompetent adults with newly diagnosed PCNSL treated at our institution between1996 and 2017. Methods We identified 66 patients who attained complete response (CR) after completion of first-line regimen; 20 received maintenance therapy (maintenance therapy group) and 46 were observed with serial MRI scans without maintenance therapy (no-maintenance therapy group). Results Compared to the surveillance group, there was a significant increase in duration of survival (HR 0.27, 95% CI 0.08-0.98, P = 0.046) in the maintenance therapy group while the reduction in the risk of progression was not significant (HR: 0.61, 95% CI 0.26-1.43, P = 0.259). Conclusion We are evaluating the effectiveness of maintenance immunotherapy in PCNSL in a prospective multicenter randomized clinical trial.

引用

页码：171 / 176

页数：6

共 50 条

[41] Primary Central Nervous System Lymphoma
Bhagavathi, Sharathkumar
Wilson, Jon D.
[J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2008, 132 (11) : 1830 - 1834
[42] Primary central nervous system lymphoma
Citterio, Giovanni
Reni, Michele
Gatta, Gemma
Ferreri, Andres Jose Maria
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 113 : 97 - 110
[43] Primary lymphoma of the central nervous system
Dalmau, J
[J]. REVISTA ECUATORIANA DE NEUROLOGIA, 1997, 6 (03): : 62 - 66
[44] Primary central nervous system lymphoma
Pels H.
Schlegel U.
[J]. Current Treatment Options in Neurology, 2006, 8 (4) : 346 - 357
[45] Primary central nervous system lymphoma
DeAngelis, LM
[J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (06): : 699 - 701
[46] Primary central nervous system lymphoma
[J]. Nature Reviews Disease Primers, 9
[47] Primary central nervous system lymphoma
Abrey, Lauren E.
[J]. CURRENT OPINION IN NEUROLOGY, 2009, 22 (06) : 675 - 680
[48] Primary central nervous system lymphoma
DeAngelis, LM
[J]. CURRENT OPINION IN NEUROLOGY, 1999, 12 (06) : 687 - 691
[49] Primary Central Nervous System Lymphoma
Gerstner, Elizabeth R.
Batchelor, Tracy T.
[J]. ARCHIVES OF NEUROLOGY, 2010, 67 (03) : 291 - 297
[50] Primary Central Nervous System Lymphoma
Gallop-Evans, E.
[J]. CLINICAL ONCOLOGY, 2012, 24 (05) : 329 - 338

← 1 2 3 4 5 →